NASDAQ:ABUS Arbutus Biopharma Q3 2025 Earnings Report $4.78 -0.09 (-1.75%) As of 09:58 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Arbutus Biopharma EPS ResultsActual EPS-$0.04Consensus EPS -$0.05Beat/MissBeat by +$0.01One Year Ago EPSN/AArbutus Biopharma Revenue ResultsActual Revenue$0.53 millionExpected Revenue$1.31 millionBeat/MissMissed by -$781.00 thousandYoY Revenue GrowthN/AArbutus Biopharma Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time7:00AM ETUpcoming EarningsArbutus Biopharma's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Arbutus Biopharma Earnings HeadlinesArbutus Biopharma (NASDAQ:ABUS) Stock Crosses Above 200-Day Moving Average - Time to Sell?July 2, 2026 | americanbankingnews.comArbutus Biopharma Corporation (ABUS) Reports Q1 2026 ResultsJune 13, 2026 | finance.yahoo.com4th of July Chaikin flash saleMarc Chaikin - the 60-year Wall Street veteran who called Nvidia before it surged 45,000% - is running his first-ever 4th of July flash sale through July 6th only. His Power Gauge Report membership comes with a free year of access to his Power Gauge Rating system, a 100% money-back guarantee, and a Hotlist of buy and sell ideas - including a little-known Nvidia partner he calls 'an upgrade to Tesla stock' in the autonomous vehicle race. His tools are used on Bloomberg and Reuters terminals worldwide and have helped investors grow assets by as much as 69,000%.July 6 at 1:00 AM | Chaikin Analytics (Ad)Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comArbutus Biopharma: A Fascinating HBV Story, But Still Too EarlyMay 13, 2026 | seekingalpha.comArbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026May 1, 2026 | finance.yahoo.comSee More Arbutus Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arbutus Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arbutus Biopharma and other key companies, straight to your email. Email Address About Arbutus BiopharmaArbutus Biopharma (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core. In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics. This LNP platform underpins the company’s RNAi assets and has been the foundation for collaborations with other biopharmaceutical organizations seeking efficient delivery systems for mRNA and RNA-based medicines. Arbutus’ focus on innovative delivery solutions complements its antiviral drug discovery capabilities, positioning it at the forefront of HBV research and development. Founded through the merger of Tekmira Pharmaceuticals and OnCore Biopharma, Arbutus maintains dual operations in Warminster, Pennsylvania, and Vancouver, British Columbia. The company’s leadership team combines experience in virology, lipid chemistry and pharmaceutical development, supporting strategic alliances with academic institutions and contract research organizations worldwide. Arbutus continues to engage with global regulatory authorities to advance its clinical trials and seeks partnerships to broaden the reach of its potential HBV therapies.View Arbutus Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponVisa’s Open USD Push Puts Circle’s Stablecoin Moat Under PressureGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off? Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
